At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 354 enrolled
Drug / intervention
LY900014 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro in Combination With Insulin Glargine or Insulin Degludec in Adults With Type 1 Diabetes
In Brief
A Phase 3 clinical trial evaluating LY900014, Insulin Lispro, and 2 other interventions for Type 1 Diabetes Mellitus. Completed, enrolled 354 participants across 30 sites in 3 countries.
Detailed Summary
The purpose of this study is to see if LY900014 compared to insulin lispro (Humalog), both in combination with insulin glargine or insulin degludec, is safe and effective in participants with type 1 diabetes (T1D).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes Mellitus
CountriesArgentina, China, Mexico
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedMay 2019
Enrollment StartMay 2019
Primary CompletionJan 2022
TodayJul 2026
First PostedMay 16, 2019
Enrollment StartMay 29, 2019
Primary CompletionJan 10, 2022
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 7.1 years ago
Interventions
LY900014drug
Administered SC
Insulin Lisprodrug
Administered SC
Insulin Glarginedrug
Administered SC
Insulin Degludecdrug
Administered SC